You just read:

DIFICLIR[TM] (Fidaxomicin) Significantly Reduces Recurrence and All-Cause Mortality When Used First-Line in All Patients Diagnosed With Clostridium Difficile Infection (CDI)

News provided by

Astellas Pharma EMEA

19 May, 2015, 15:03 BST